Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Journal of the American Academy of Dermatology

- PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Around 64 million people worldwide live with psoriasis

- PMLiVE

Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in difficult-to-treat plaque psoriasis

An estimated eight million people in the US are living with the immune-mediated skin disease

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

- PMLiVE

Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis

Plaque psoriasis affects up to 90% of patients with the immune-mediated disease

- PMLiVE

FDA approves Organon’s Vtama cream to treat atopic dermatitis in adults and children

More than 26 million people in the US are affected by the inflammatory skin disease

- PMLiVE

J&J and Protagonist share promising phase 3 results for icotrokinra in plaque psoriasis

More than 125 million people globally are estimated to be living with the skin disorder

- PMLiVE

Dermavant reports positive long-term results for Vtama cream in atopic dermatitis

More than 26 million people in the US are affected by the inflammatory skin condition

- PMLiVE

Johnson & Johnson’s Tremfya shows promise in ‘special site’ plaque psoriasis

The immune-mediated disease affects more than 125 million people worldwide

- PMLiVE

Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis

At least 100 million people worldwide are affected by the immune-mediated disease

- PMLiVE

Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

Nearly 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

UCB reveals positive phase 3 results for Bimzelx in moderate-to-severe plaque psoriasis

Affecting 90% of psoriasis patients, the chronic autoimmune disease causes red, itchy, scaly patches

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links